Endometrial carcinoma in tamoxifen-treated breast cancer patient: Clinicopathological, immunohistochemical, and genetic analysis

International Journal of Gynecological Pathology

Volumn 18, Issue 4, 1999, Pages 387-391

  Esteller, Manel ^a   Garcia, Angel ^b   Martinez Palones, Josep Maria ^b   Xercavins, Jordi ^b   Reventos, Jaume ^b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b HOSPITAL MATERNO INFANTIL VALL D HEBRON   (Spain)

Author keywords

Endometrial cancer; Estrogen receptor; Genetic alterations; K ras; Susceptibility; Tamoxifen

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); CYCLIN D1; DNA; ESTROGEN RECEPTOR; ETHOXYRESORUFIN DEETHYLASE; PROGESTERONE RECEPTOR; PROTEIN P53; TAMOXIFEN;

AGED; ARTICLE; BREAST CANCER; CASE REPORT; CLINICAL FEATURE; CODON; DNA METHYLATION; DOSE RESPONSE; ENDOMETRIUM CARCINOMA; FEMALE; GENETIC ANALYSIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYSTERECTOMY; IMMUNOHISTOCHEMISTRY; ONCOGENE C ERB; ONCOGENE K RAS; POINT MUTATION; PRIORITY JOURNAL;

EID: 0032831839     PISSN: 02771691     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004347-199910000-00015     Document Type: Article

References (22)

1. Assikis VJ, Neven P, Jordan VC, Vergote I. A realistic clinical perspective of tamoxifen and endometrial carcinogenesis. Eur J Cancer 1996;32:1464-76.
2. Fisher B, Costantino JP, Redmond CK, Fisher ER, Wickerman DL, Cronin WM. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 1994;86: 527-37.
3. Magriples U, Naftolin F, Schwartz PE, Cargangiu ML. High grade endometrial carcinoma in tamoxifen-treated breast cancer patients. J Clin Oncol 1993;11:485-90.
4. Silva EG, Tornos C, Malpica A, Mitchell MF. Uterine neoplasms in patients treated with tamoxifen. J Cell Biochem 1995;523:179-83.
5. Ziegler J. Endometrial cancers from tamoxifen are not more aggressive. J Natl Cancer Inst 1996;88:1101.
6. Esteller M, Garcia A, Martinez-Palones JM, Xercavins J, Reventos J. Detection of clonality and genetic alterations in endometrial pipelle biopsy and its surgical specimen counterpart. Lab Invest 1997;76:109-16.
7. Esteller M, Garcia A, Martinez-Palones JM, Xercavins J, Reventos J. Susceptibility to endometrial cancer: influence of allelism at p53, glutathione S-transferase (GSTM1 and GSTT1) and cytochrome P-450 (CYP1A1) loci. Br J Cancer 1997;75:1385-8.
8. Esteller M, Garcia A, Martinez-Palones JM, Cabero A, Reventos J. Detection of c-erbB2/neu and fibroblast growth factor-3/INT-2 but not epidermal growth factor receptor gene amplification in endometrial cancer by differential polymerase chain reaction. Cancer 1995;75:2139-46.
9. Esteller M, Garcia A, Martinez-Palones JM, Xercavins J, Reventos J. Germ line polymorphisms in cytochrome-P450 1A1 (C4887 CYP1A1) and methylenetetrahydrofolate reductase (MTHFR) genes and endometrial cancer susceptibility. Carcinogenesis 1997; 18:2307-11.
10. Noguchi M, Rose DP, Miyazaki I. Breast cancer chemoprevention-Clinical trials and research. Oncology 1996;53:175-81.
11. Killackey MA, Hakes TB, Pierce VK. Endometrial adenocarcinoma in breast cancer patients receiving antiestrogens. Cancer Treat Rep 1985;69:237-8.
12. Gottardis MM, Robinson SP, Satyaswaroop PS, Jordan VC. Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse. Cancer Res 1988;48:812-5.
13. Gusberg SB. Tamoxifen for breast cancer: associated endometrial cancer. Cancer 1990;65:1463-4.
14. Anzai Y, Holinku C, Kuvamoto H. Stimulatory effects of 4-hydroxy tamoxifen on proliferation of human endometrial adenocarcinoma cells. Cancer Res 1989;49:2362-5.
15. Grenman SE. In vitro growth regulation of endometrial carcinoma cells by tamoxifen and medroxy progesterone acetate. Gynecol Oncol 1988;30:239-50.
16. Kuwashima Y, Kurosumi M, Kobayashi Y, et al. Tamoxifen mediated human endometrial carcinogenesis may not involve estrogenic pathways. Anticancer Res 1996;16:2993-6.
17. Hemminski K, Rajaniemi H, Lindahl B, Moberger B. Tamoxifen-induced DNA adducts in endometrial samples from breast cancer patients. Cancer Res 1996;56:4374-7.
18. Boyd J. Molecular biology in the clinicopathologic assessment of endometrial carcinoma subtypes. Gynecol Oncol 1996;61:163-5.
19. Esteller M, Garcia A, Martinez-Palones JM, Xercavins J, Reventos J. The clinicopathological significance of K-ras point mutation and gene amplification in endometrial cancer. Eur J Cancer 1997;33: 1572-7.
20. Laird P, Jaenisch R. The role of DNA methylation in cancer genetics and epigenetics. Annu Rev Genet 1996;30:441-64.
21. Kleinz Z, Ben-Baruch G, Marciano D, Solomon R, Altaras M, Kloog Y. Characterization of the prenylated protein methyltransferase in human endometrial carcinoma. Biochim Biophys Acta 1994;3:330-6.
22. Piva R, Kumar VL, Hanau S, Rimondi AP, Pansini S, Mollica G, del Senno L. Abnormal methylation of estrogen receptor gene and reduced estrogen receptor RNA levels in human endometrial carcinomas. J Steroid Biochem 1989;32:1-4.